Chemistry:ZED1227

ZED1227
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name Methyl (E,6S)-7-[[1-[2-(2-ethylbutylamino)-2-oxoethyl]-2-oxopyridin-3-yl]amino]-6-[(1-methylimidazole-4-carbonyl)amino]-7-oxohept-2-enoate;
PubChem CID	168775562;
Chemical and physical data
Formula	C26H36N6O6
Molar mass	528.610 g·mol−1

Short description: Chemical compound

ZED1227 is a transglutaminase 2 (TG2) inhibitor developed by Zedira GmbH for celiac disease^[1]^[2] and nonalcoholic steatohepatitis.^[3]

References

↑ Schuppan, Detlef; Mäki, Markku; Lundin, Knut E.A.; Isola, Jorma; Friesing-Sosnik, Tina; Taavela, Juha; Popp, Alina; Koskenpato, Jari et al. (1 July 2021). "A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease". New England Journal of Medicine 385 (1): 35–45. doi:10.1056/NEJMoa2032441. PMID 34192430.
↑ Büchold, Christian; Hils, Martin; Gerlach, Uwe; Weber, Johannes; Pelzer, Christiane; Heil, Andreas; Aeschlimann, Daniel; Pasternack, Ralf (17 May 2022). "Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease". Cells 11 (10): 1667. doi:10.3390/cells11101667. PMID 35626704.
↑ "CTG Labs - NCBI". https://clinicaltrials.gov/study/NCT05305599?start=2019-11-03_&aggFilters=funderType:industry,phase:2%203&limit=100&cond=NASH&rank=93.

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/ZED1227. Read more

Legal status

Legal status	Investigational
Identifiers
IUPAC name Methyl (E,6S)-7-[[1-[2-(2-ethylbutylamino)-2-oxoethyl]-2-oxopyridin-3-yl]amino]-6-[(1-methylimidazole-4-carbonyl)amino]-7-oxohept-2-enoate
PubChem CID	168775562
Chemical and physical data
Formula	C₂₆H₃₆N₆O₆
Molar mass	528.610 g·mol⁻¹